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Abstract
Increased cancer stem cell content during development of resistance to tamoxifen in breast cancer is driven by multiple
signals, including Sox2-dependent activation of Wnt signalling. Here, we show that Sox2 increases and estrogen reduces the
expression of the transcription factor Sox9. Gain and loss of function assays indicate that Sox9 is implicated in the
maintenance of human breast luminal progenitor cells. CRISPR/Cas knockout of Sox9 reduces growth of tamoxifen-resistant
breast tumours in vivo. Mechanistically, Sox9 acts downstream of Sox2 to control luminal progenitor cell content and is
required for expression of the cancer stem cell marker ALDH1A3 and Wnt signalling activity. Sox9 is elevated in breast
cancer patients after endocrine therapy failure. This new regulatory axis highlights the relevance of SOX family transcription
factors as potential therapeutic targets in breast cancer.
Introduction
Breast cancer is a very heterogeneous disease. Analysis of
the gene expression proﬁles of breast carcinomas has
revealed the existence of various tumour subtypes with
clinical implications [1]. Further studies, including the
integrated analysis of copy number and gene expression,
have revealed the presence of a novel molecular
stratiﬁcation [2]. These molecular classiﬁcations reﬂect the
genetic diversity of breast tumours among patients. How-
ever, there is another level of complexity at the tumour
level, as each tumour is not a mass of a single type of cell,
but a mixture of different cell types, including cells with
characteristics of stem/progenitor cells. It appears that both
stem cells and luminal progenitors could be targets of
transformation, giving rise to different cancer subtypes [3].
The mammary epithelium is composed of two main
cellular lineages, luminal and myoepithelial and, in addi-
tion, stem and progenitor cells responsible for ductal lobular
outgrowth. Various approaches have been used to identify
breast cells with characteristics of stem cells, including the
expression of speciﬁc cell surface markers, such as EMA
and CALLA [4] and CD49f and EpCAM (ESA) [5, 6],
which identify normal breast stem/progenitor cells. In
addition, high CD44 and low CD24 (CD44+CD24−/low) [7],
as well as elevated aldehyde dehydrogenase (ALDH)
activity [8] and increased mammosphere-forming capacity
[9], have been conﬁrmed as methods that enrich for cells
with characteristics of cancer stem cells (CSCs), as assayed
by increased tumour initiation potential in transplantation
studies. Cells referred to as CSCs or tumour-initiating cells
drive tumour initiation and growth and, in addition, CSCs
are also more resistant than non-CSCs to current forms of
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therapy, including radiotherapy [10], chemotherapy [11]
and hormone therapy [12].
Studies in our laboratory showed that the increase of
CSCs during development of resistance to tamoxifen is
driven by enhanced levels of Sox2 [12]. Genetic proﬁling of
Sox2 overexpressing cells [12] revealed increased expres-
sion of Sox9 in these cells. Sox9 is a member of the high
mobility group (HMG) superfamily of transcription factors
that is expressed in progenitor or stem cells in multiple
tissues, including the skin, pancreas, intestine and liver
[13–16]. In the mammary gland, Sox9 cooperates with the
transcription factor Slug to orchestrate the stem cell state
[17]. In the mouse, Sox9 has been shown to be a key re-
gulator of mammary gland development and stem/pro-
genitor cell maintenance [18] and, in breast cancer patients,
high-Sox9 expression has been associated with estrogen
receptor (ER)-negative tumours, signiﬁcantly shorter over-
all survival and poor survival [19].
Here, we show that Sox9 expression, which is directly
induced by Sox2, marks luminal progenitors in normal
human breast epithelial cells and in breast CSCs. We further
show that Sox9 expression is repressed by estrogen, re-
gulates the luminal progenitor population by directly indu-
cing ALDH1A3 expression and that Sox9 knockout using
CRISPR restores sensitivity to tamoxifen in vivo. Finally,
Sox9 expression is required for Wnt signalling in breast
cancer cells. Our observations support a model in which
Sox9 is required for the maintenance of luminal progenitors
in the human breast and for Wnt signalling in tamoxifen-
resistant breast cancer cells.
Results
Sox9 expression in normal human breast epithelial
cells
We wished to examine Sox9 expression in different epi-
thelial cell populations in the human mammary gland. To
this end, breast epithelial cells were isolated from
reduction mammoplasties and FACS sorted according to
different phenotypes. First, membrane markers CD49f
and EpCAM were used to distinguish between mature
luminal cells (CD49f−EpCAM+), luminal progenitor cells
(CD49f+EpCAM+), myoepithelial/stem cells (CD49f
+EpCAM−) and negative/stromal cells (CD49f−EpCAM−)
[6, 20] (Supplementary Fig. S1a). Western blot (Fig. 1a)
and immunoﬂuorescence (Fig. 1b) analyses of FACS sorted
cells from ﬁve reduction mammoplasties showed that Sox9
is predominantly expressed by the double-positive CD49f
+EpCAM+ luminal progenitor cell subset and, to a lesser
extent, by CD49f−EpCAM+ luminal cells (patient char-
acteristics are shown in Supplementary Table S1). Second,
we examined Sox9 levels in cells with increased aldehyde
dehydrogenase (ALDH) activity (ALDEFLUOR-positive or
ALDH+) since these cells have been shown to display stem/
progenitor cell properties [8]. Sox9 expression was sig-
niﬁcantly higher in ALDH+ than in ALDH− cells, as
observed by western blot (Fig. 1c) and immunoﬂuorescence
(Fig. 1d), further indicating preferential expression in stem/
progenitor cells.
On the basis of Sox9 upregulation both in luminal pro-
genitors and in ALDH+ primary breast epithelial cells, we
analysed the degree of overlap of these two cell sub-
populations. Indeed, fractionation of ALDH+ and ALDH−
cell populations from primary human breast epithelial cell
samples using CD49f and EpCAM markers showed that
the majority of ALDH+ cells were found within
the luminal progenitor cell population (81.9% ± 5.8% are
CD49f+EpCAM+), with a lower percentage of differ-
entiated luminal cells (CD49f−EpCAM+ cells, 16.4% ±
5.9%) and an almost negligible number of CD49f+EpCAM
−(0.6% ± 0.2%) or CD49f−EpCAM− cells (1.1% ± 0.8%).
On the other hand, the ALDH− cells were found mostly in
the mixed myoepithelial/stem cell compartment (62.7% ±
8.2%) (Supplementary Fig. S1b). These ﬁndings indicate
that Sox9 marks ALDH+ and CD49f+EpCAM+ luminal
progenitor cells in the human breast.
Sox9 expression regulates luminal progenitor cell
fate
ALDEFLUOR activity has been shown to be a marker of
normal and malignant human mammary stem cells [8] and
Sox9 has been implicated in determining the mammary
stem cell state [17]. We therefore tested the possible func-
tional role of Sox9 in maintaining the ALDH+ cell popu-
lation in the human mammary gland. Primary human breast
epithelial cells from three different donor samples were
stably transduced using lentiviral-mediated delivery of
control and Sox9 shRNA constructs (Supplementary Fig.
S2a). ALDEFLUOR assays showed a signiﬁcant decrease
in the percentage of the ALDH+ population in cells with
reduced Sox9 levels (Fig. 2a and Supplementary Fig. S2b).
Furthermore, stable Sox9 silencing in primary human breast
epithelial cells led to reduced primary and secondary
mammosphere formation (Fig. 2b), inhibition of cell pro-
liferation in 2D (Supplementary Fig. S2c) and in 3D, with
reduced formation of acini in Matrigel, as compared to
controls (Fig. 2c). Conversely, overexpression of Sox9 in
the breast epithelial cell line MCF10A (Supplementary Fig.
S2d) resulted in an increase in colony formation, in the
numbers of acini with an irregular shape and ﬁlled lumens
(Fig. 2d) and in the ALDH+ cell population (Fig. 2e and
Supplementary Fig. S2e), compared to control-transduced
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cells, suggesting that Sox9 contributes to the maintenance
of the stem/progenitor pool in the human breast epithelium.
In order to determine whether Sox9 expression levels
inﬂuence the differentiation potential of progenitor cells, the
number of multilineage colonies generated by shcontrol and
shSox9 breast epithelial cells was tested by culture on
collagen. The percentage of cells with bilineage differ-
entiation potential (mixed colonies, K18+K14+) was unaf-
fected (Fig. 2f). In contrast, silencing of Sox9 clearly
reduced the number of luminal colonies (K18+) formed,
while myoepithelial colonies (K14+) increased (Fig. 2f). In
addition, colonies were also stained for Muc-1 (as a luminal
marker) and p63 (as a basal marker), supporting this ﬁnding
(Supplementary Fig. S2f). These results support the
hypothesis that Sox9 regulates lineage speciﬁcation by
human luminal progenitors. Finally, we analysed expression
levels of genes involved in luminal/myoepithelial cell dif-
ferentiation (GATA3, ELF5 and α-SMA), progenitor cell
markers (ALDH1A3 and c-KIT), stemness factors, includ-
ing FOXO3A and SNAI2/SLUG, and also ER, PR, AREG
and FOXA1. Sox9 silencing in primary epithelial cells
signiﬁcantly reduced the expression of progenitor and
luminal markers and ER signalling pathway genes, and
induced expression of the myoepithelial marker α-SMA
(Fig. 2g). Together, these ﬁndings indicate that Sox9 is
required for the maintenance of the mammary stem/pro-
genitor cell pool in the human breast epithelium and for
commitment to the luminal epithelial lineage.
Sox9 is highly expressed in breast tumours
compared to normal tissue
Sox9 is important for determining the mammary stem cell
state both in normal and breast cancer cell lines [17]. We
therefore determined whether Sox9 expression levels were
altered in breast tumour samples using quantitative real-time
PCR and western blotting. Sox9 expression was analysed in
a cohort of 30 human primary breast tumours and adjacent
normal breast tissue from the same patients. A signiﬁcant
increase in Sox9 expression levels was observed in tumour
samples compared to their normal counterparts, both at the
mRNA (Fig. 3a) and protein level (Fig. 3b), which also
showed the high variability present in primary breast tis-
sues. Additionally, some pairs of normal and tumour sam-
ples were probed for the luminal marker Muc-1 in parallel
to Sox9, and the results were consistent with Sox9 being
Fig. 1 Sox9 marks luminal progenitor cells and ALDEFLUOR+cells
in the human breast. a Sox9 protein levels in CD49f-EpCAM−, CD49f
+EpCAM−, CD49f+EpCAM+ and CD49f−EpCAM+ cell populations
from three different primary human breast epithelial cell samples were
assessed by western blot. b Immunoﬂuorescence analysis of Sox9
expression in CD49f−EpCAM−, CD49f+EpCAM−, CD49f+EpCAM+
and CD49f−EpCAM+ cell populations sorted from primary human
breast epithelial cells from one tissue sample, as representative
example. c Sox9 levels in ALDEFLUOR− (indicated as ALDH−) and
ALDEFLUOR+ (indicated as ALDH+) cells sorted from three differ-
ent human breast epithelial cell samples. d A representative example of
immunoﬂuorescence analysis of Sox9 expression in ALDEFLUOR−
and ALDEFLUOR+ cells sorted from human breast epithelial cells
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more highly expressed in tumour cells than in normal cells
(Supplementary Fig. S3a). Similar to our ﬁndings in normal
breast tissue, ALDH+ tumour cells expressed signiﬁcantly
higher levels of SOX9 mRNA (Fig. 3c) and Sox9 protein
(Fig. 3d) than ALDH− cells (patient information can be
found in Supplementary Table S2). Moreover, analysis of
Fig. 2 Modulation of Sox9
levels alters human mammary
stem cell phenotype.
a ALDEFLUOR assay in
primary breast epithelial cells
stably transduced with shcontrol
(shc) and shSox9 lentivirus
(n= 4). b Primary (I MS) and
secondary (II MS)
mammosphere formation in
primary human breast epithelial
cells transduced with shcontrol
(shc) and shSox9 lentivirus (n=
5). c Colony formation assay on
Matrigel of primary epithelial
cells stably transduced with
shcontrol (shc) and shSox9
lentivirus (n= 4). A
representative image is shown.
d Colony formation assay on
Matrigel of MCF10A cells
stably transduced with plenti6.2-
GFP c or pLenti6.2-Sox9 (Sox9)
(n= 4). A phase-contrast (left)
and a confocal
immunoﬂuorescence (right)
images of acini stained for
CD49f-APC (green), Phalloidin
(red) and DAPI (blue) are
shown. The pie graphs show
percentage of MCF10A colonies
growing as acini in Matrigel
displaying different types of
lumen (hollow, half-ﬁlled/half-
hollow and ﬁlled).
e ALDEFLUOR assay in
MCF10A cells stably transduced
with pLenti6.2V.DEST (c) and
pLenti6.2-Sox9 (Sox9) (n= 5).
f Luminal (keratin 18, K18+),
myoepithelial (keratin 14, K14+)
and mixed (K18+K14+)
colonies formed on collagen-
coated wells from human
primary breast epithelial cells
transfected with shcontrol (−) or
shSox9 (+). Results are shown
as fold change in number of
colonies compared to shcontrol
cells (n= 3). Representative
colony images are shown.
g Relative transcript levels of the
indicated genes in shSox9
primary human breast epithelial
cells compared to shcontrol cells
(n= 4/5). Error bars represent
standard deviation (SD). *p <
0.05, **p < 0,001, statistical test:
two-tail t-test
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an online database (GSE52327) that compared the expres-
sion proﬁles of ALDH− and ALDH+ cell populations iso-
lated from breast cancer samples, also showed higher SOX9
mRNA levels in ALDH+ than in ALDH− cells (Supple-
mentary Fig. S3b). These ﬁndings suggest that Sox9 could
also be expressed in cells with tumour-initiating capacity,
Fig. 3 Sox9 is highly expressed
in human breast tumours.
a SOX9 mRNA expression
levels in human breast tumour
(T) samples compared to their
normal (N) counterparts (n=
13). b Immunoblot of Sox9 and
β-actin (loading control) in a set
of ER-positive and ER-negative
breast tumours (T) compared to
the corresponding normal (N)
and peritumoral (P) tissue (n=
11). c Transcript levels of SOX9
in ALDH− and ALDH+ cells
sorted from 8 different human
primary breast tumours.
d Immunoﬂuorescence analysis
of Sox9 expression in ALDH−
and ALDH+ cells sorted from a
primary breast tumour, as
representative example. e SOX9
mRNA (left) and Sox9 protein
(right) levels in ER-positive
(MCF7, T47D, and ZR-75–1)
and ER-negative (MDA-MB-
231 and MDA-MB-468) breast
cancer cells, relative to levels in
MCF7 cells, set as 1.
f Immunoﬂuorescence analysis
of Sox9 and ER expression in
MCF7, T47D and ZR-75-1
breast cancer cells. *p < 0.05,
statistical test: Mann–Whitney
test a; *p < 0.05, **p < 0,001,
statistical test: two-tail t-test e
A Sox2–Sox9 signalling axis maintains human breast luminal progenitor and breast. . .
since ALDH+ cells have been shown to be able of self-
renewal and increased tumour generation in xenotransplant
models [8, 21].
Despite the relatively small sample number, it appeared
that Sox9 expression was strongest in ER-negative tumours
(Fig. 3b). To support this observation, we examined SOX9
mRNA levels in publicly available breast tumour datasets.
Analysis of a cohort of patients (n= 99, GSE2603)
conﬁrmed that SOX9 expression is signiﬁcantly higher in
ER-negative than in ER-positive tumours (Supplementary
Fig. S3c). Examination of the GOBO database (Gene
Expression-Based Outcome for Breast Cancer Online) fur-
ther conﬁrmed these ﬁndings (Supplementary Fig. S3d) and
also showed highest SOX9 expression levels in the most
aggressive basal/triple-negative breast cancer cell lines
(Supplementary Fig. S3e) and reduced recurrence-free sur-
vival in patients with basal-like breast cancer (Supplemen-
tary Fig. S3f).
Finally, we also examined Sox9 expression in several
ER-positive (MCF7, T47D and ZR75-1) and ER-negative
(MDA-MB-231 and MDA-MB-468) breast cancer cell lines
and found that, as in breast tumour samples, Sox9 is more
highly expressed in cell lines lacking ER than in ER-
positive cells, both at the mRNA and protein levels
(Fig. 3e). Furthermore, immunoﬂuorescence analysis of
MCF7, ZR75-1 and T47D cells indicated that those cells
with the lowest ER levels expressed the highest Sox9 levels,
while cells with strong nuclear ER lacked Sox9 (Fig. 3f).
Together, these ﬁndings highlight an inverse correlation
between Sox9 and ER expression in breast cancer cells and
indicate that Sox9 expression is found in both luminal
progenitor cells and more aggressive breast tumours.
ER represses Sox9 expression
On the basis of the inverse correlation observed between
Sox9 and ER expression, we hypothesized that Sox9
expression may be regulated by estrogen in breast cancer
cells. Indeed, treatment of MCF7 cells with 10–8 M estrogen
led to a strong downregulation of SOX9 mRNA in a time-
dependent manner, while the expression of PS2, a well-
known ER target gene, was increased in parallel (Fig. 4a).
This reduction was also observed at the protein level in
different ER-positive breast cancer cell lines (Fig. 4b).
Fig. 4 Sox9 expression is
repressed by estrogen.
a Transcript levels of SOX9 and
PS2/TFF1 expression in MCF7
cells after 10−8 M estrogen (E2)
treatment (n= 3).
b Immunoblots of Sox9 in
MCF7, T47D and ZR-75-1 cells
treated for 2 days with 10−8 M
estrogen. c SOX9 mRNA (left)
and Sox9 protein (right) levels
after 10–7 M ICI 182,780
treatment in MCF7 cells (n= 3).
d Immunoblots for Sox9 in
MCF7, T47D, ZR-75–1 and
their corresponding tamoxifen-
resistant breast cancer cells
(parental (c) and TamR,
respectively). β-actin, GAPDH
or Hsp60 have been used as
loading controls, as indicated.
Error bars represent standard
deviation (SD). *p < 0.05,
statistical test: two-tail t-test,
compared to control a, c
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Furthermore, treatment of MCF7 cells with the ER-
antagonist fulvestrant (ICI 182,780), which leads to degra-
dation of ER protein, resulted in a signiﬁcant recovery
of Sox9 expression, both at the mRNA and protein level
(Fig. 4c), suggesting that ER is a critical regulator of Sox9
transcription. Furthermore, in silico analysis of GEO data-
sets conﬁrmed that silencing of ER in MCF7 cells results in
enhanced SOX9 mRNA expression (Supplementary Fig.
S4a).
Our observations suggest that Sox9 regulation by estro-
gen may be relevant for the self-renewal or differentiation
commitment of stem/progenitor cells. Development of
resistance to hormone treatment in ER-positive breast can-
cer is a major clinical problem in cancer management. We
have previously shown that estrogen reduces the progenitor
cell pool [22] and that CSCs are implicated in the devel-
opment of resistance to tamoxifen, a process that compro-
mises ER transcriptional activity [12]. Based on this, it
could be hypothesized that Sox9 levels are increased in cells
resistant to tamoxifen. Indeed, analysis of three models of
tamoxifen resistance developed in our laboratory, based on
parental MCF7, T47D and ZR75-1 cells [12], showed that
SOX9 mRNA (Supplementary Fig. S4b) and Sox9 protein
(Fig. 4d) levels were clearly upregulated in tamoxifen-
resistant cells. Together, these ﬁndings indicate that ER
inhibits Sox9 expression.
These ﬁndings raise the possibility that ER directly
represses Sox9. ER target genes are regulated by binding of
ER to response elements (EREs) [23]. A genome-wide
screen for high-afﬁnity binding sites identiﬁed a potential
ERE near the transcription start site (−2650) of SOX9
conserved in human and mouse [24]. However, chromatin
immunoprecipitation (ChIP) assay failed to detect any sig-
niﬁcant binding of ER to this site of the human SOX9
promoter (Supplementary Fig. S4c), while there was very
strong binding to the PS2 promoter, used as a positive
control, suggesting that Sox9 regulation by estrogen is not
direct. Similarly, stable transduction of ER into ER-negative
MDA-MB-231 cells failed to reduce Sox9 expression
(Supplementary Fig. S4d), suggesting that additional factor
(s) may be required for negative regulation by ER. More-
over, ectopic expression of ER in MDA-MB-231 cells has
varied effects on the expression of ER-regulated genes,
most likely a result of the absence of co-factors, such as
FOXA1 and GATA3, which have been shown to be
required to restore estrogen‐responsive growth to MDA-
MB-231 cells [25].
Sox9 silencing impairs stem cell self-renewal
Mammosphere formation capacity and serial passage in
suspension can be used to assess stem cell self-renewal, one
of the hallmarks of stem cells, and the number of spheres
formed in suspension has been shown to correlate with stem
cell content [9, 12]. As previously shown for Sox2 [12],
Sox9 expression was elevated in ER-positive (MCF7,
Fig. 5a), ER-negative (MDA-MB-468, Fig. 5b) and
tamoxifen-resistant (MCF7TamR, Fig. 5c) cells cultured in
suspension, compared to cells growing in adherent condi-
tions, indicating that Sox9 is upregulated in conditions that
enrich for cells with characteristics of stem cells. Further-
more, both primary and secondary mammosphere formation
efﬁciency was diminished in MCF7TamR cells by reducing
Sox9 expression levels using two different
shSox9 sequences (Fig. 5d and Supplementary Fig. S5a)
and also in triple-negative breast cancer cells (Fig. 5e and
Supplementary Fig. S5b). Conversely, Sox9 overexpression
in MCF10A cells was sufﬁcient to increase primary and
secondary mammosphere formation in a modest but statis-
tically signiﬁcant manner (Fig. 5f). Additionally, deletion of
endogenous Sox9 using CRISPR/Cas in MCF7TamR cells
(Supplementary Fig. S5c) led to a signiﬁcant reduction in
their capacity for mammosphere formation in all clones
tested (Fig. 5g). Finally, this reduction in the ability to form
mammospheres was fully restored by exogenous expression
of Sox9 (Fig. 5h). These ﬁndings suggest that Sox9 is
implicated in the self-renewal capacity of progenitor cells in
different breast cancer cell types, including in tamoxifen-
resistant cells.
Sox9 regulates ALDH activity through ALDH1A3
Next, we wished to investigate further the functional
implication of Sox9 in stem/progenitor cell maintenance in
tamoxifen-resistant cells. As previously observed in normal
and tumour progenitors, Sox9 was predominantly expressed
in the ALDH+ population isolated from tamoxifen-resistant
cells (Fig. 6a). Stable Sox9 silencing using three different
shRNA sequences (Supplementary Fig. S6a) signiﬁcantly
reduced ALDH+ cell content in MCF7 and T47D
tamoxifen-resistant cells (Fig. 6b, Supplementary Fig. S6b).
A similar effect was achieved using siRNA oligonucleotides
to reduce endogenous Sox9 expression in MCF7TamR cells
(Supplementary Fig. S6c). In addition, CRISPR/Cas dele-
tion of Sox9 signiﬁcantly reduced ALDEFLUOR activity in
MCF7TamR cells (Fig. 6c), again conﬁrming the relevance
of Sox9 expression for ALDH activity.
ALDH1A3 has been reported to be the most important
ALDH isoform responsible for ALDH activity in breast
cancer cells, representing a marker of poor prognosis in
breast cancer patients [25] and correlating with increased
ALDH activity in tamoxifen-resistant cells [12]. Indeed,
ALDH1A3 expression was signiﬁcantly increased in
MCF7TamR cells both at the mRNA (Fig. 6d) and protein
(Supplementary Fig. S6d) level. Reduction of endogenous
Sox9 levels using speciﬁc shRNA sequences inhibited
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ALDH1A3 expression, both in MCF7 and T47D tamoxifen-
resistant cells (Supplementary Fig. S6e), as did CRISPR/
Cas deletion of Sox9 (Fig. 6e). On the other hand, over-
expression of Sox9 in MCF10A cells led to enhanced
ALDH1A3 expression (Fig. 6f). To determine whether the
reduced ALDH1A3 expression observed by deletion of
Sox9 could be rescued, Sox9 was ectopically expressed into
Sox9-deﬁcient MCF7TamR cells. Indeed, ectopic Sox9
Fig. 5 Sox9 regulates breast
cancer stem cell renewal.
Transcript levels of SOX9 and
SOX2 in MCF7 (a) and MDA-
MB-468 (b) breast cancer cells
cultured in adherent (Adh) or
suspension conditions, as
primary (I MS) and secondary
(II MS) mammospheres (n= 3).
c Immunoblot of Sox9 and β-
actin (loading control) in MCF7
and MCF7TamR cells cultured
in adherent (Adh) or suspension
(I MS) conditions. d Primary (I
MS) and secondary (II MS)
mammosphere formation in
MCF7TamR cells stably
transduced with shcontrol (shc)
and 2 different
shSox9 sequences (1 and 2)
lentivirus (n= 4/5).
e Mammosphere formation in
MDA-MB-231 and BT549
triple-negative breast cancer
cells stably transduced with
shcontrol (−) and shSox9 (+)
lentivirus (n= 3). f Primary (I
MS) and secondary (II MS)
mammosphere formation in
MCF10A cells stably transduced
with control c and Sox9
plasmids (I MS: n= 4; II MS n
= 3). g Mammosphere
formation in sgRNA binding
sense strand only as control (c)
and four different CRISPR/
Cas9n clones using a pair of
sgRNAs for both DNA strands,
resulting in Sox9 deletion,
derived from MCF7TamR cells
(n= 4). h Mammosphere
formation in control (c) and
Sox9 knockout (clone 1)
MCF7TamR cells by CRISPR/
Cas9n editing (CRISPR Sox9),
as in g. Control and
MCF7TamR cells lacking Sox9
were stably transfected with an
empty expression vector (vector)
or a vector expressing Sox9
(Sox9) and mammosphere
formation was quantiﬁed, with
the control cells set as 1 (n= 3).
Error bars represent standard
deviation (SD), p-value *p <
0.05, **p < 0.001 compared to
control e, statistical test: two
tailed t-test a, b, e, f, g, one-way
Anova d, h
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expression (Supplementary Fig. S6f) was sufﬁcient to
restore ALDH1A3 expression levels to those observed in
parental cells (Fig. 6g), as well as ALDEFLUOR activity
(Supplementary Fig. S6g). Finally, to assess whether Sox9
regulates ALDH1A3 expression directly, ALDH1A3 pro-
moter sequences were analysed using the JASPAR database
(http://jaspar.genereg.net/). Chromatin immunoprecipitation
showed-speciﬁc Sox9 binding to two different regions of
Fig. 6 Sox9 expression associates with ALDEFLUOR activity.
a Immunoblot of Sox9, and β-actin as loading control, in ALDE-
FLUOR– and ALDEFLUOR+ cells sorted from MCF7TamR cells.
b Fold change of ALDEFLUOR+ cells in MCF7TamR and
T47DTamR shcontrol (−) and shSox9 (+) cells, (n= 4). c Fold
change of ALDEFLUOR+ cells in sgRNA binding sense strand only,
as control (c) and Sox9 knockout (4 different clones) MCF7TamR
cells by CRISPR/Cas9n editing (n= 3). d ALDH1A3 mRNA
expression in parental MCF7 and MCF7TamR (TamR) cells (n= 3).
e ALDH1A3 mRNA expression levels in sgRNA control (c) and Sox9
knockout (4 different clones) MCF7TamR cells by CRISPR/Cas9n
editing (n= 3). f ALDH1A3 mRNA expression in MCF10A-GFP (c)
and MCF10A-Sox9 (Sox9) cells (n= 5). g ALDH1A3 expression
levels in sgRNA control (c) and Sox9 knockout MCF7TamR cells by
CRISPR/Cas9n editing. The MCF7TamR cells lacking Sox9 were
stably transfected with an empty expression vector (vector) or a vector
expressing Sox9 (Sox9). h Chromatin Immunoprecipitation (ChIP)
showing Sox9 binding to human ALDH1A3 promoter in MCF7TamR
cells at two positions, A (845 bp) and B (1828 bp) upstream from the
transcription start site. Data are shown as fold enrichment compared to
IgG binding (n= 4). Error bars represent standard deviation (SD). *p
< 0.05, compared to control, statistical test: two-tail t-test
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the ALDH1A3 promoter (Fig. 6h), similarly to that
observed in the TCF4 promoter, which was used as a
control (Supplementary Fig. S6h). These ﬁndings indicate
that Sox9 controls luminal progenitor cell content by reg-
ulating ALDH1A3 levels.
Reduced Sox9 expression enhances tamoxifen
sensitivity in vivo
To determine the effects of Sox9 signalling in breast cancer
tumorigenicity, we analysed cell clonogenicity, migration
Fig. 7 Sox9 expression is implicated in tumorigenicity in vitro and
in vivo. a Soft agar colony formation assay in MCF7TamR shcontrol
(shc) and shSox9 cells with different concentrations of tamoxifen (10
−9–10−7 M), (n= 4). b Soft agar colony formation assay in
MCF7TamR, T47DTamR and MDA-MB-231 shcontrol (−) and
shSox9 (+) cells (n= 3). c Cell invasion assay of MDA-MB-231
shcontrol (−) and shSox9 (+) cells invading through Matrigel in
Transwell plates (n= 3). d Representative images of MDA-MB-231
spheroids grown in Matrigel at the indicated time points from wild
type (wt), sgRNA binding sense strand only as control (c) and a
CRISPR/Cas9n clone using a pair of sgRNAs for both DNA strands,
resulting in Sox9 deletion (CRISPR) cells. Below each photograph the
analysis of the invaded area by ImageJ is shown and their quantiﬁ-
cation represented in the graph (n= 3). Arrows indicate areas of
invasion. e Soft agar colony formation assay in wild type (wt), sgRNA
control (c) and 4 different CRISPR/Cas9n-mediated deletion of Sox9
clones (1–4) in MDA-MB-231 cells (n= 3). f Soft agar colony for-
mation assay in MCF7 cells stably transduced with an empty vector (v)
or a Sox9 expression vector (Sox9) and treated with 10–9 M or 10–8 M
tamoxifen (n= 4). g Tumour volumes from mammary tumours from
each cohort (sgRNA control (c) or CRISPR/Cas9n-mediated deletion
of Sox9 (CRISPR Sox9) in MCF7TamR cells) collected 18 weeks
after injections into mammary fat pad four in NSG female mice in the
presence of an exogenous slow oestrogen supplement and a tamoxifen
pellet (n= 4–6 tumours/group). 100 cells, p= 0.0028; 1000 cells, p=
0.0423. Mann–Whitney test was used. Statistic test: t-test (a, b, c) and
one-way Anova (e, f). Error bars represent standard deviation (SD). P,
p-value: *p < 0.05, **p < 0.001
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and invasion capacity. Stable Sox9 silencing in tamoxifen-
resistant cells signiﬁcantly enhanced tamoxifen sensitivity
(Fig. 7a), suggesting that the number of progenitors, and
therefore of hormone-insensitive cells, was reduced. Fur-
thermore, Sox9 silencing reduced the capacity of
tamoxifen-resistant cells and triple-negative breast cancer
cells to form colonies (Supplementary Fig. S7a), inhibited
anchorage-independent growth in soft agar (Fig. 7b) and
signiﬁcantly reduced capacity for invasion (Fig. 7c). In
addition, the cell invasion capacity of MDA-MB-231 cells
in 3D spheroid cultures was reduced in cells with CRISPR/
Cas Sox9 deletion, which only formed tight spheroids that
were unable to invade (Fig. 7d, Supplementary Fig. S7b).
Furthermore, reduced anchorage-independent growth in soft
agar was observed in all deletion clones tested (Fig. 7e).
Deletion or silencing of Sox9 in cancer cells led to a clear
change in cell morphology, from a characteristic spindle-
like morphology to a cobblestone-like monolayer (Supple-
mentary Fig. S7c and S7d). On the other hand, we have
previously observed that Sox9 overexpression in non-
tumorigenic MCF10A cells was sufﬁcient to induce irre-
gular morphology (Fig. 2d), while ectopic expression of
Sox9 in MCF7 cells was sufﬁcient to increase their resis-
tance to tamoxifen (Fig. 7f). We recently reported that
Sox9 silencing in MDA-MB-231 cells reduces tumour
formation capacity in vivo [17, 26]. To test the effects of
Sox9 on tamoxifen sensitivity in vivo, MCF7TamR cells
deleted for Sox9 using CRISPR/Cas were orthotopically
transplanted into the mammary fat pads of mice. In vivo
limiting dilution assay (102, 103, 4 × 104, 106 cells) showed
that in contrast to control tamoxifen-resistant cells, Sox9
null cells implanted at low cell density were unable to form
substantial tumours in the presence of tamoxifen (Fig. 7g).
ELDA (extreme limiting dilution analysis) assay demon-
strated that lack of Sox9 signiﬁcantly reduced the frequency
of tumour-initiating cells by 4.76-fold (p= 0.00427) in
tamoxifen-resistant cells (Supplementary Fig. S7e). Toge-
ther, the data suggest that Sox9 enhances tumour stemness,
leading to increased tamoxifen resistance in vivo.
Sox9 activates Wnt signalling
Previously we showed that the development of tamoxifen
resistance is driven by Sox2-dependent activation of Wnt
signalling in cancer stem/progenitor cells [12]. Given the
implication of Sox9 in progenitor cells, we determined the
effect of Sox9 silencing on two of the Wnt pathway genes
identiﬁed by microarray [12]. Intriguingly, Sox9 inhibition
(whether transient or stable) resulted in signiﬁcantly
reduced expression of AXIN2, a classical Wnt/β-catenin
target gene (Fig. 8a and Supplementary Fig. S8a) and of the
Wnt receptor and target gene FZD4 (Fig. 8b), in tamoxifen-
resistant cells and in triple-negative breast cancer cells.
Furthermore, Wnt/β-catenin transcriptional activity, assayed
using a TOP/FOP luciferase reporter, was impaired in cells
with reduced Sox9 levels, compared to parental cells
(Supplementary Fig. S8b).
To investigate further the relationship between Wnt
signalling and Sox9, two classes of small molecules that
inhibit Wnt signalling were used, the porcupine inhibitor
IWP-2, which inhibits Wnt secretion, and IWR-1, which
decreases β-catenin levels by stabilising axin. In both cases,
inhibition of Wnt signalling resulted in a signiﬁcant
reduction of the progenitor ALDH+ cell population
(Fig. 8c) in tamoxifen-resistant cells, mimicking the effect
observed with Sox9 silencing. On the other hand, addition
of Wnt3a to activate Wnt signalling, resulted in an increase
in the capacity of MCF7TamR cells to form mammo-
spheres, as expected. However, this increase was not
observed in cells with either reduced endogenous levels of
Sox9 (Supplementary Fig. S8c) or a total lack of Sox9 (Fig.
8d). Furthermore, while activation of Wnt signalling by the
GSK3β inhibitor CHIR99021 increased mammosphere
formation in control cells, it was unable to rescue mam-
mosphere formation in cells deleted for Sox9 (Supplemen-
tary Fig. S8d), suggesting Sox9 is also required at a point in
the Wnt signaling pathway downstream of β-catenin
stabilization.
Our previous microarray analysis identiﬁed SOX9 as a
target of Sox2 [12] and showed that ectopic Sox2 expres-
sion leads to increased Sox9 levels (Fig. 8e). We therefore
wished to explore further the relationship between these two
Sox family factors. Cells with high endogenous levels of
Sox2 and Sox9 (MCF7TamR, BT549 and MDA-MB-231
cells) that were transiently silenced for Sox9, presented a
signiﬁcant inhibition in SOX2 expression (Fig. 8f),
although this effect was not observed when using cells
stably silenced for Sox9 (Supplementary Fig. S8e), sug-
gesting a potential compensatory mechanism to recover
SOX2 expression. Conversely, silencing of Sox2 in MDA-
MB-231 cells reduced both SOX9 and AXIN2 expression
(Fig. 8g, h). Sox2 silencing did not further reduce expres-
sion of the Wnt target gene AXIN2 in Sox9-silenced cells
(Fig. 8h), suggesting Sox9 may required for Sox2 to acti-
vate Wnt signalling in these cells. In addition, in order to
explore whether this regulation involved direct DNA
binding, chromatin immunoprecipitation was performed.
Speciﬁc Sox2 binding was observed to consensus DNA
binding sequences identiﬁed in the SOX9 promoter (http://
jaspar.genereg.net/) (Fig. 8i). Binding was modest but sig-
niﬁcant and similar to the observed binding of Sox2 to
DNA target sequences identiﬁed in the cyclin D1 promoter
[27]. On the other hand, speciﬁc Sox9 binding was also
detected to consensus DNA sequences on the SOX2
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promoter (http://jaspar.genereg.net/) (Fig. 8i), conﬁrming
that Sox2 and Sox9 can regulate one another at the tran-
scriptional level. Immunoﬂuorescence analysis showed that
Sox2 and Sox9 are coexpressed in some cells within the
population of tamoxifen-resistant cells (Supplementary Fig.
S8f).
Together, these ﬁndings suggest a signaling network
(Fig. 8j) that includes a regulatory loop in which Sox2 and
Sox9 regulate one another, leading to activation of Wnt
signalling.
Fig. 8 A Sox2–Sox9 axis regulates Wnt activity in breast cancer cells.
AXIN2 a and Fzd4 b mRNA expression levels in MCF7TamR and
MDA-MB-231 cells stably transduced with shcontrol (−) and shSox9
(+) lentiviral vectors (n= 3/4). c Relative change in the proportion of
ALDEFLUOR+ cells in MCF7TamR and T47DTamR cells treated
during 48 h with IWP-2 or IWR-1 Wnt inhibitors (n= 3). d Mam-
mosphere formation in sgRNA binding sense strand only as control (c)
and two different CRISPR/Cas9n clones with Sox9 deletion, derived
from MCF7TamR cells in the absence (carrier containing CHAPS) or
presence of Wnt3a (n= 4). e Sox9 protein expression levels in control
(c) and Sox2 overexpressing (Sox2) MCF7 cells, with β-actin as
control. f Sox2 and Sox9 mRNA expression levels in MCF7TamR,
BT549 and MDA-MB-231 cells transiently transfected with sicontrol
(−) or siSox9 (+) sequences (n= 3). g SOX9 and h AXIN2 mRNA
expression levels in MDA-MB-231 shcontrol (shc) and shSox9 cells
transiently transfected with sicontrol (−) and siSox2 (+) sequences (n
= 3). i Chromatin Immunoprecipitation (ChIP) showing Sox2 binding
to the human cyclin D1 and SOX9 promoters (left) and Sox9 binding
to the human ALDH1A3 and SOX2 promoters (right). IgG control
binding is set as 1 (n= 3). Error bars represent standard deviations
(SD). *p < 0.05, **p < 0.001 compared to control. Statistic test: two-
tail t-test (a, b, c, d, f, g) and Anova (i). j Model shows reciprocal
regulation between Sox2 and Sox9 leading to activation of ALDH1A3
in breast cancer cells. Dashed arrow shows regulation of Wnt target
genes by Sox2 [12], which may involve Sox9 (this report). ER
negatively regulates both Sox2 and Sox9. The Sox2–Sox9 axis con-
tributes to increased tamoxifen resistance
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Discussion
In this study, we demonstrate that Sox9 is implicated in the
maintenance of luminal progenitor cells in the human breast
and regulates the ALDH+ luminal progenitor cell popula-
tion. Some breast cancers express high levels of Sox9,
especially tumours resistant to tamoxifen and ER-negative
tumours. This is may be partly due to the observed
estrogen-dependent reduction of Sox9 expression in breast
cancer cells. Deletion of Sox9 renders tamoxifen-resistant
cells unable to form tumours under tamoxifen pressure
in vivo. Direct binding of Sox9 to the ALDH1A3 promoter
increases the ALDH+ cell population. Finally, we report
that Sox2 activation of Wnt signalling requires Sox9. These
ﬁndings reveal a crucial role for Sox9 in maintaining
luminal progenitors in the human breast and CSCs in breast
cancer.
Sox9 has been shown to be relevant in the regulation and
maintenance of stem/progenitor cells in the mouse mam-
mary gland [17]. However, little is known regarding the
mechanism of action of Sox9 in stem/progenitor cells in the
human breast, and our studies shed light on this issue. Our
ﬁndings show that CD49f+EpCAM+ cells are ALDH+ and
that Sox9 marks both cell populations in human primary
breast epithelial cells. ALDEFLUOR-positive cells repre-
sent luminal progenitor cells in the human breast [8] and
stem cells in the hematopoietic system [28]. CD49f
+EpCAM+ cells have also been identiﬁed as luminal pro-
genitor cells, owing to their capacity to undergo differ-
entiation into milk-producing cells upon a lactogenic
stimulus [6] and to form budding structures at clonal density
[20].
Sox9 and Slug have been shown to cooperate to specify
the stem cell state [17] in mice. Immunoﬂuorescence ana-
lysis of Slug and Sox9 showed double-positive cells in a
small percentage (14.11% ± 2.62%) of luminal progenitor
cells (Supplementary Fig. S1c). Here we show that silencing
endogenous Sox9 expression in primary human epithelial
cell populations was sufﬁcient to reduce luminal progenitor
activity. This suggests that Sox9 is important to regulate cell
plasticity in the human mammary gland. Indeed, a condi-
tional Sox9 knockout mouse model shows impaired mam-
mary gland formation as well as reduced numbers of
luminal mammary progenitor cells [18]. On the other hand,
overexpression of Sox9 in vivo increases mammary ductal
branching [29]. Together, these ﬁndings reinforce the rele-
vance of Sox9 in the human breast for luminal progenitor
cell maintenance and differentiation. In addition, Sox9 is
also implicated in the maintenance of stem and progenitor
cells in neural stem cells [30], pancreatic progenitor cells
[31], retinal multipotent mouse progenitor cells [32], lung
epithelial progenitors [33], kidney epithelial regeneration
[34] and during prostate development [35], suggesting a
developmentally conserved role in stem/progenitor cell
regulation.
In cancer, however, the role of Sox9 is more diverse.
Various studies have found that Sox9 represents a negative
prognostic factor in different types of cancer, including
glioma [36] and lung [37]. In contrast, Sox9 has been
reported to be a tumour suppressor in cervical cancer [38].
Its role in other cancers remains controversial, for example,
in melanoma, Sox9 has been reported to be protective [39]
or represent a negative prognostic factor [40]. Varied
prognostic associations have also been reported in prostate
[41, 42], colorectal cancer [43, 44] and bladder cancer [45,
46]. These mixed observations may reﬂect a context-
dependent regulatory role for Sox9 in some tissues.
Our analysis of breast tumour samples reveals elevated
levels of Sox9, compared to normal tissue, particularly in
patients with ER-negative and in tamoxifen-resistant
tumours, as previously described [19, 47]. Analysis of
several public datasets conﬁrmed that Sox9 expression is
signiﬁcantly increased in ER-negative and basal-like
tumours, in agreement with previous work [19]. Con-
sistent with this, in ER-positive tumour cells, Sox9 does not
co-localise with ER. Similar results were found in the
normal breast, in which luminal progenitor cells, which
express very low levels of ER [6], are enriched in Sox9
expression. This may be partly explained by the observation
that estrogen reduces Sox9 expression in ER-positive cells,
resulting in high Sox9 levels in ER-negative tumour cells
and in tamoxifen-resistant cells, likely due to their reduced
ER activity [12]. The hormone-dependent inhibition of
Sox9 is in agreement with our previous reports on the
effects of estrogen contributing to a more differentiated
phenotype by reducing the stem cell pool in the human
breast [22, 23] and the association between high CSC
content and poorly differentiated tumours [48, 49].
Previous in vivo xenograft studies [17, 26] have shown
that Sox9 silencing in MDA-MB-231 breast cancer cells
reduces tumour formation. Recently, Sox9 expression was
reported to be increased in breast tumour samples after the
development of resistance and overexpression of Sox9 in
MCF7 cells was shown to confer resistance to tamoxifen in
in vitro cell proliferation assays [47]. Our orthotopic tumour
transplantations further demonstrate that Sox9 expression is
required for tamoxifen resistance in vivo, which may
explain the increase in Sox9 levels observed in clinical
samples from patients that have developed resistance to
tamoxifen.
Enhanced ALDH activity is known to represent stem/
progenitor cells in the mammary gland [8]. ALDH1A3 is an
important contributor to Aldeﬂuor activity in breast cancer
and its expression is predictive of metastasis [25]. Similarly,
ALDH1A3 expression is a determinant in malignant pleural
mesothelioma cell resistance to chemotherapy [50] and in
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liver cancer [51], suggesting that it could be a new ther-
apeutic target. We found that Sox9 induces ALDH1A3
expression directly, while its silencing reduces ALDH1A3
mRNA levels, resulting, in both cases, in altered Aldeﬂuor
activity. In addition, Sox9 levels control mammosphere
formation, suggesting that Sox9 is important for progenitor
self-renewal. Consistent with this, the transcriptional proﬁle
of human normal mammary stem cells with the capacity to
retain the dye PKH26, shows increased SOX9 expression
levels [48]. Together, these ﬁndings argue for the relevance
of Sox9 in maintaining the luminal progenitor cell popula-
tion in the breast and suggest a cell-of-origin for transfor-
mation within this cellular compartment. However, it is
important to emphasise that cell plasticity is higher than
originally anticipated and cells may be able to alter their
differentiation status in response to various intra- and
extracellular signals [52].
We previously reported that Sox2 is a marker of breast
stem cells [22] and that its expression is reduced by estro-
gen [12]. The observed increase in SOX9 upon ectopic
Sox2 expression and the reduction in SOX2 expression
upon silencing of Sox9, together with their reciprocal
binding of Sox2 and Sox9 to their respective promoters,
suggest a positive regulatory feedback loop between these
transcription factors. Both Sox2 and Sox9 silencing reduce
Wnt target gene expression and Sox2 silencing reduces
expression of SOX9 and AXIN2. However, further inhibi-
tion of AXIN2 expression was not observed in the absence
of Sox9, suggesting that Sox2 acts upstream of Sox9. Sox2
and Sox9 do not form heterodimers [53], so these effects are
unlikely to be mediated by a direct Sox2–Sox9 interaction.
Various pathways have been reported to regulate normal
breast and cancer stem cells. Among them, the Wnt sig-
nalling pathway appears to be particularly relevant in the
breast. Wnt signals are implicated in normal breast devel-
opment [54] and in maintaining stem/progenitor cells in the
human breast [55]. In breast cancer, Wnt signalling is
associated with invasion, metastasis and poor survival [56–
59]. Notably, we have previously shown that Sox2 activates
Wnt signalling in hormone-resistant cells [12] and now ﬁnd
that Sox9, itself a Wnt-responsive gene [15, 60], also reg-
ulates Wnt signalling, in agreement with the observed
association between Sox9 and the expression of Wnt/β-
catenin components LRP6 and Tcf4 in breast cancer [29].
Similarly, it has been shown that Sox9 positively regulates
multiple genes required for Wnt signalling in prostate
cancer [61]. Furthermore, neither Wnt3a nor CHIR99021
treatment rescued mammosphere formation in cells with
reduced levels of Sox9. Together, these observations reveal
a positive-feedback loop that implicates Sox2 and Sox9 in
the activation of Wnt signalling.
In conclusion, these ﬁndings identify a Sox2–Sox9 net-
work as crucial for stem/progenitor cell maintenance in the
human mammary gland and warrant further research into
the potential of Sox family transcription factors as ther-
apeutic targets in certain types of breast cancer.
Materials and methods
Cell culture
MCF7, T47D, ZR-75-1, MCF10A, MDA-MB-231, BT549
and MDA-MB-468 were obtained from the American Type
Culture Collection (ATCC). The MCF7, T47D and ZR-75-1
tamoxifen-resistant cell lines were previously developed in
the laboratory [12]. MCF10A were cultured as previously
reported [62], all the other cell lines were cultured in
DMEM:F-12 medium with GlutaMAX (Gibco) supple-
mented with 8% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin at 37 °C in 5% CO2. For hormone
treatments with 17-β-estradiol (Sigma) or Fulvestrant (ICI
182,780), cells were hormone depleted for 72 h in phenol-
red free DMEM/F-12 medium supplemented with 8%
charcoal-stripped FBS. All cell lines were routinely checked
for mycoplasma contamination. Mammosphere cultures
were maintained as previously described [12]. When
required, Wnt inhibitors were used at 2 µM (IWP-2 and
IWR-1) or 1 µM (CHIR99021) ﬁnal concentration and
DMSO was used as vehicle diluted 1/1000 in cell culture
medium as control.
Primary human breast epithelial cells
Normal breast tissue was obtained from women (n= 5)
undergoing reduction mammoplasty with no previous
history of breast cancer (Supplementary table S1) and
cells cultured as mammospheres, as previously described
[63]. Tumour samples were obtained from core biopsies
or from women undergoing therapeutic surgery (n= 32)
and included paired normal and tumour tissue from the
same patient. All samples were reviewed by a consultant
breast pathologist. Patients provided written informed
consent, and the procedures were approved by the local
Hospital Research Ethics Committee and by the ‘Ethics
Committee of Clinical Investigation of Euskadi’. The
breast tissue was immediately processed as previously
described [4, 22].
Stable shRNA clones from primary human breast epi-
thelial cells were cultured with WIT-P-NCTM Medium
(Cellaria) supplemented with 1% penicillin/streptomycin.
All the experiments using primary breast cells were per-
formed until passage 4 in culture, to avoid signs of reduced
cell growth and senescence.
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Growth assays
For differentiation assays, human breast epithelial cells
(1000 cells/well) were seeded on glass coverslips previously
coated with collagen and cultured with WIT-P-NCTM
Medium (Cellaria) supplemented with 1% penicillin/strep-
tomicin. Culture medium was replaced every 3 days in all
assays. Formed colonies were ﬁxed in paraformaldehyde
4% for immunoﬂuorescence analysis.
For acinar formation in Matrigel (BD Biosciences),
human breast epithelial cells or MCF10A cells, 1000 cells/
well in 96-well plates, were seeded on top of a layer of
Matrigel. Colonies were counted under the light microscope
or stained for immunoﬂuorescence analysis.
For clonogenic assays, breast cancer cells were seeded at
500 cells/well in a 6-well plate. Colonies were ﬁxed and
stained with a 0.2% crystal violet, 20% methanol solution
and counted.
To assess anchorage-independent growth, soft agar col-
ony formation assays were used. Brieﬂy, 10,000 cells/well,
in a 6-well plate, were cultured in triplicate in complete
medium with 0.35% low-melting agar over a bottom layer
with 0.7% regular agar until visible colonies were formed
and counted.
Lentiviral stable expression
A set of three pLKO.1 lentiviral vector shRNAs targeting
Sox9 was purchased from Open Biosystem (source ID:
TRCN0000020384, TRCN0000020385,
TRCN0000020386). An empty vector and a shRNA against
a random sequence, shcontrol, were used as negative con-
trols. Lentiviruses were produced by transfection of 293T
packaging cells with a 3-plasmid system. Stably transduced
cells were selected by culturing with 2 µg/ml puromycin for
2 days and then maintained in medium containing 0.5 µg/ml
puromycin. Stable Sox9 downregulation was assessed by
western blot. Sox9 overexpression was achieved using a
plenti6.2-GFP (or pLenti6.2-V-DEST for Aldeﬂuor assays)
and plenti6.2-Sox9 (kindly provided by Vincent J Hearing,
NCI). Brieﬂy, for ER overexpression, ERα cDNA was
cloned using XhoI and EcoRI restriction sites into plenti6.2-
V-DEST vector.
Fluorescence activated cell sorting (FACS)
For CD49f/EpCAM stainings, FITC-conjugated anti-
EpCAM antibody (Stemcell Technologies, 10110) and
APC-conjugated anti-CD49f antibody (eBioscience, 17-
0495-80) were used. Control samples were stained with
isotype-matched control antibodies, the viability dye 7-
aminoactinomycin D (7AAD) (BD) was used for dead cell
exclusion, and ﬂuorescence minus one (FMO) controls were
used to deﬁne the gates [64]. Approximately 100,000 pri-
mary cells were FACS sorted and then cytospun on poly-
lysine coated slides for immunoﬂuorescence analysis. To
measure ALDH activity in cells, ALDEFLUOR assay
(Stemcell Technologies) was carried out according to
manufacturer’s guidelines, and as previously described [22].
Cells were sorted using a FACSAria (Becton Dickinson)
ﬂow cytometer and the data were analysed using the
FACSDiva software.
Western blot
Cell extracts were prepared as previously described [65] and
analysed using the following primary antibodies: rabbit
anti-Sox9 (Millipore, AB5535), rabbit anti-ALDH1A3
(Abgent, RB16818), mouse anti-GAPDH (Sigma, G8795),
mouse anti-β-actin (AC-15/A5441), mouse anti-ERα
(Novocastra Leica Biosystems, NCL-ER-6F11), Armenian
hamster anti-Muc-1 (ThermoFisher Scientiﬁc, MA5-
11202), mouse anti-β-tubulin (Sigma, T4026) and rabbit
anti-Hsp60 (Santa Cruz Biotechnology, sc-13966). For
detection an enhanced chemiluminescence detection kit
(Bio-rad) was used.
Immunoﬂuorescence
Approximately 100,000 primary cells were FACS sorted
and then cytospun on poly-lysine coated slides. Cell lines
were grown directly on slides and processed as previously
described [66]. Brieﬂy, cells were ﬁxed with 4% paraf-
ormaldehyde (Santa Cruz Biotech.), permeabilised with
0.5% Triton X-100, blocked for 1 h with 3% BSA and
stained with the primary antibodies rabbit anti-Sox9 (Mil-
lipore, AB5535), goat anti-Sox2 (Santa Cruz Biotech, sc-
17320) and mouse anti-ERα (Novocastra Leica Biosystems,
NCL-ER-6F11), and then with anti-rabbit Alexa 488
(Thermo Fisher Scientiﬁc, A21206), anti-mouse Alexa 594
(Thermo Fisher Scientiﬁc, A21203), anti-goat Alexa-488
(Thermo Fisher Scientiﬁc, A11055) secondary antibodies.
Finally, slides were mounted in Vectashield with DAPI
(Vector Laboratories) and visualized on a Leica confocal
microscope.
Differentiated colonies from human breast epithelial cells
were stained with the following primary antibodies, mouse
anti-K14 (IgG3) (Vector, VPC410) and mouse anti-K8/18
(IgG1) (Bio Rad, MCA1864HT) or Armenian hamster anti-
Muc-1 (Thermo Fisher Scientiﬁc, MA5-11202) and mouse
anti-P63 (Ventana, 790–4509) and secondary antibodies,
anti-mouse IgG3 Texas-Red (Southern Biotech, 1100–07)
and anti-mouse IgG1 FITC (Southern Biotech, 1070–02) or
anti-Armenian hamster Cy3 (Jackson Immuno Research,
127-165-160) and anti-mouse Alexa 488 (Thermo Fisher
Scientiﬁc, A21202).
A Sox2–Sox9 signalling axis maintains human breast luminal progenitor and breast. . .
MCF10A cell acini were stained according to the pro-
tocol from Joan Brugge’s lab [67]. Brieﬂy, MCF10A acini
growing on Matrigel were ﬁxed with 4% paraformaldehyde
for 20 min at 4 °C, followed by permeabilisation with 0.5%
Triton X-100, 10 min at 4 °C and blocked with 3% BSA.
Acini were incubated overnight with a rat anti-human
CD49f APC-conjugated antibody (eBIOscience, 17-4321-
41), followed by DAPI (Sigma) and Phalloidin-TRITC
staining.
In order to analyse Sox9 and Slug co-localization, cells
were ﬁxed with 100% methanol for 15 min at 4 °C, fol-
lowed by blocking with 3% BSA-0.1% Triton X-100 in
PBS and stained overnight with primary Sox9 antibody.
Two rounds of 1 h of the secondary antibody anti-rabbit
Alexa-594 incubation were performed. Then, cells were
blocked with 5% BSA-PBS for 6 h prior to overnight rabbit
anti-Slug (Thermo Fisher Scientiﬁc, PA1-86737) primary
antibody incubation, followed by 20 min incubation with
anti-rabbit Alexa488 antibody. Finally, slides were mounted
in Vectashield with DAPI (Vector Laboratories) and ana-
lysed using a Leica confocal microscope.
Transient transfections
Transient transfections and luciferase assays were per-
formed as previously described [12]. Brieﬂy, 40,000 cells
were seeded in triplicate in 24-well plate and the following
day transfected. The reporter plasmids used included
8XTOPﬂash and 8XFOPﬂash, SOX-luciferase, with seven
copies of the AACAAAG SOX-binding element or the
control SAC-luciferase, with seven copies of the
CCGCGGT sequence as negative control (both kindly
provided by Dr Philippe Jay, IGF, Montpellier) reporter
plasmids and pRL β-galactosidase as control for transfec-
tion efﬁciency. Results are shown as TOP/FOP transcrip-
tional activity in shSox9 cells versus shcontrol cells, set as
1.
Small interfering RNA oligonucleotides were transfected
using Lipofectamine 2000 or Lipofectamine RNAiMax
(Invitrogen) following the guidelines of the manufacturer
and as previously described [52]. Silencing was conﬁrmed
by western blot or qRT-PCR. The RNAi sequences used
are:
sicontrol (commercial siMISSION, Sigma);
siSox9 (1):UGAAGAAGGAGAGCGAGGAGGACAA;
siSox9 (2):UUGUCCUCCUCGCUCUCCUUCUUCA
and
siSox2: CCUGUGGUUACCUCUUCCUCCCACU.
Real-time polymerase chain reaction (qPCR)
RNA was isolated using the Machery-NagelNucleoSpin®
RNA, according to instructions of the manufacturer.
Real-time PCR was performed on a ViiA 7 or a Quant-
Studio 6 Flex Real-Time PCR Systems (Applied Bio-
systems) and as previously described [12]. Primer
(Invitrogen) sequences can be found in Supplementary
Table S3.
Invasion assay
Invasion and migration assays were performed in a 24-well
BD FalconTM HTS Multiwell Insert System containing an
8 µm pore size PET (PolyEthyleneTerepthalate) membrane,
as previously described [12].
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed following manufacturer´s
instructions (SimpleChIP® Enzymatic Chromatin IP Kit,
Magnetic beads, Cell Signaling). Brieﬂy, at least 107 cells
were cross-linked with 1% formaldehyde and the reaction
quenched by 1M glycine. Cells were lysed and nucleic
acids were digested using Micrococcal nuclease for 20 min
at 37 °C. Digestion was followed by sonication to shear
chromatin and storage at −80 °C for subsequent chromatin
immunoprecipitation. Chromatin was subjected to RNAse
and Proteinase K treatment and followed by DNA pur-
iﬁcation. Chromatin was incubated overnight with control
rabbit IgG and Sox9 antibody (AB5535, Millipore), and a
positive control against Histone 3 (H3) was used to check
the enrichment of the RPL30 gene. Before immunopreci-
pitation, 2% of the diluted chromatin was removed and
stored at −20 °C for subsequent DNA puriﬁcation and used
as “chromatin input”. The next day, protein G-magnetic
beads were added to the chromatin—antibody solution.
Chromatin was eluted and protein-DNA crosslink reversal
was obtained using Proteinase K. Bounded DNA was pur-
iﬁed and qRT-PCR was carried out using a ViiA 7 qPCR
system (Applied Biosystems) using primers that amplify the
predicted Sox9 binding region in the ALDH1A3 promoter
as follows: “A” site F: GATTAGCAGCAAAGGTCT
CATGT, R: ACACCGCCTTCCATCCCAGA; “B” site: F:
GGAGCAGAGTTCTAAGCTCAA, R: GAAATTATGT
CACTGCCAGG. Sox9 binding in Sox2 promoter: F:
GTAAGAGAGGAGAGCGGAAGAG, R: CGGCTGTCC
AACTCGTATTTCT. Sox2 binding in Sox9 promoter: F:
CCAGAGTGGAGCGTTTTGTC, R: TGTCTGGGGGA
GAGTTTGCTA. Sox2 binding site in Cyclin D1 promoter:
F: TGCCGGGCTTTGATCTTT, R: CGGTCGTTGAG
GAGGTTGG. ERα binding site on PS2 promoter: F:
TGGGCTTCATGAGCTCCTTC, R: TTCATAGTGAGA
GATGGCCGG. Putative ERα binding site on Sox9 pro-
moter: F: TGAACATCAGGAGCGGGTT, R: ATTCA
GGGGCTCCATTCGCT.
G. Domenici et al.
Sox9 targeting using CRISPR-Cas9n technology
A pair of sgRNA primers targeting the ﬁrst Sox9 exon were
designed and cloned into the nickase plasmid pSpCas9n
(BB)−2A-Puro (PX462, Addgene). sgRNA oligo sequen-
ces were: sgRNA A, 5′-TTCAGATCGGGCTCGCCCTT-
3′ and B, 5′-CCCCGTGTGCATCCGCGAGG-3′. Cells
were transiently transfected with the resulting Cas9n vector
together with 1 (for the control) or the 2 sgRNA sequences
against Sox9, using Lipo2000 reagent (Invitrogen®),
according to manufacturer’s instructions. Two days after
transfection, stably transfected cells were selected with 2 μg/
ml puromycin and single-cell clones were picked, sub-
cultured and ampliﬁed. DNA was extracted using the
QuickExtractTM DNA Extraction Solution (Epicentre) for
sequencing, according to manufacturer’s instructions.
Genotyping PCR was performed using 2 primers ﬂanking
the Cas9n target site (F: 5′-CCGTCGGGCTCCG
GCTCGGAC-3′, R: 5′-CTCCAGAGCTTGCCCAGCGT
C-3′).
Spheroid formation assay
In order to avoid cell adherence to the plastic surface, round
bottom 96-well plates (Sarsted) were coated with 200 μl of
poly(2-hydroxyethylmethacrylate) (poly-HEMA [Sigma])
and dried overnight at 56 °C. The next day, 5000 cells were
seeded in duplicate in 200 μl of complete medium. Spher-
oids were allowed to form for 4 days and after careful
medium removal, 50 μl of Matrigel growth factor reduced
(BD) was added on the top of the spheroids, allowed to
solidify and covered with medium, which was replenished
every 3–4 days. Spheroid growth and cell invasion was
followed daily, and the images were captured using a
camera connected to an inverted microscope. The invaded
area was quantiﬁed using ImageJ software.
Mammary fat pad xenotransplantation
NSG mice, purchased from Charles River (Harlow, UK),
were housed in individually ventilated cages on a 12-h light/
dark cycle, and received food and water ad libitum. All
work was carried out under UK Home Ofﬁce projects and
personal licenses following receipt of local ethical approval
from the Institute of Cancer Research Ethics Committee and
in accordance with local and national guidelines.
MCF7TamR cells were suspended in 100 μl of PBS/
Matrigel (1:1) and injected into mammary gland 4 of 10–
12-week-old female mice, which simultaneously received a
60-day slow release pellet containing 0.72 mg of 17β-
estradiol with 5 mg tamoxifen pellet (Innovative Research
of America). Cells were injected at varying numbers ran-
ging from 100 to 1 million cells/mouse). Pellets were
replaced once. Animals were observed once a week.
Tumour volumes were calculated with the formula: (Aver-
age (Rmax, Rmin)3) × 0.5236, where Rmax and Rmin are
the maximum and minimum tumour radii, respectively. The
tumour-initiating frequency was used for calculation of
frequency of cancer stem cells using the extreme limiting
dilution analysis (ELDA) software web interface (http://
bioinf.wehi.edu.au/software/elda).
Statistical analysis
Data from at least three-independent experiments are
expressed as means ± standard deviation, SD. Each data
point of real-time PCR, mammosphere formation, luciferase
activity and proliferation assays were run at least in tripli-
cates and independent experiments were performed at least
three times. Student’s t-test or Anova were used to deter-
mine statistically signiﬁcant differences and p < 0.05 was
considered to be statistically signiﬁcant unless otherwise
speciﬁed.
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